Steven G. Elliott, Ph.D.
Steve Elliott is a member of the American Kidney Fund (AKF) Board of Trustees and serves on the Medical Advisory, Clinical Scientist in Nephrology, and Kidney Disease Prevention, Education & Outreach Committees.
He received a Ph.D. in molecular biology and biochemistry in 1978 from University of California, Irvine, followed by three years studying cell division in Scotland at the University of Edinburgh under Professor J. M. Mitchison and two years in Santa Barbara, California, in the laboratory of Professor John Carbon which was performing pioneering studies on centromere structure and function while developing early recombinant DNA methodologies.
Dr. Elliott joined Amgen in 1983 as a research scientist. During his early years at the company, he performed structure-function studies on erythropoietin and the erythropoietin receptor. This work led to the discovery of darbepoetin alfa (Aranesp®), a novel erythropoiesis-stimulating agent (ESA) currently approved for treatment of anemia in patients with chronic kidney disease (CKD) and chemotherapy-induced anemia.
He is a scientific executive director at Amgen in the hematology/oncology department where he has an active research program designed to improve our understanding of how to most effectively treat anemia in CKD and other diseases.